- Home
- SLS vs LRMR Comparison
SLS vs LRMR Comparison
Compare SLS & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- LRMR
- Stock Information
- Founded
- SLS 2012
- LRMR N/A
- Country
- SLS United States
- LRMR United States
- Employees
- SLS N/A
- LRMR N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- SLS Health Care
- LRMR Health Care
- Exchange
- SLS Nasdaq
- LRMR Nasdaq
- Market Cap
- SLS 169.6M
- LRMR 191.4M
- IPO Year
- SLS N/A
- LRMR N/A
- Fundamental
- Price
- SLS $1.85
- LRMR $3.38
- Analyst Decision
- SLS
- LRMR Strong Buy
- Analyst Count
- SLS 0
- LRMR 7
- Target Price
- SLS N/A
- LRMR $17.86
- AVG Volume (30 Days)
- SLS 3.6M
- LRMR 1.3M
- Earning Date
- SLS 08-12-2025
- LRMR 08-06-2025
- Dividend Yield
- SLS N/A
- LRMR N/A
- EPS Growth
- SLS N/A
- LRMR N/A
- EPS
- SLS N/A
- LRMR N/A
- Revenue
- SLS N/A
- LRMR N/A
- Revenue This Year
- SLS N/A
- LRMR N/A
- Revenue Next Year
- SLS N/A
- LRMR N/A
- P/E Ratio
- SLS N/A
- LRMR N/A
- Revenue Growth
- SLS N/A
- LRMR N/A
- 52 Week Low
- SLS $0.77
- LRMR $1.61
- 52 Week High
- SLS $2.27
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- SLS 52.48
- LRMR 63.62
- Support Level
- SLS $1.88
- LRMR $3.30
- Resistance Level
- SLS $2.27
- LRMR $3.57
- Average True Range (ATR)
- SLS 0.17
- LRMR 0.30
- MACD
- SLS -0.00
- LRMR 0.03
- Stochastic Oscillator
- SLS 52.60
- LRMR 85.93
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.